| Customization: | Available |
|---|---|
| CAS No.: | 1092939-17-7 |
| Formula: | C17h21n6o4p |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product name: Ruxolitinib phosphate
CAS No: 1092939-17-7
Ruxolitinib phosphate is the phosphate salt form of ruxolitinib, a Janus kinase (JAK) inhibitor. It is used primarily for the treatment of certain blood-related cancers and autoimmune diseases by targeting and inhibiting JAK1 and JAK2 enzymes, which are involved in the signaling pathways that regulate blood cell production and immune responses. By blocking these enzymes, ruxolitinib phosphate helps reduce abnormal cell proliferation, inflammation, and immune activity, making it an important therapy for conditions such as myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Application and Effect
Ruxolitinib phosphate is primarily used to treat myelofibrosis and polycythemia vera, both of which are types of myeloproliferative disorders. Myelofibrosis is marked by abnormal bone marrow fibrosis, leading to poor blood cell production, while polycythemia vera involves the overproduction of red blood cells, increasing the risk of clotting. By inhibiting JAK1 and JAK2, ruxolitinib phosphate helps reduce the production of abnormal blood cells, alleviating symptoms like splenomegaly (enlarged spleen) and improving blood counts. Additionally, ruxolitinib phosphate is used in the management of graft-versus-host disease (GVHD), a complication that can occur after stem cell or bone marrow transplants. GVHD occurs when the transplanted immune cells attack the recipient's tissues. Ruxolitinib phosphate helps reduce the severity of GVHD by modulating the immune response, improving outcomes for transplant patients. Ruxolitinib phosphate has also been studied in the treatment of other inflammatory diseases, such as atopic dermatitis. It is a targeted therapy that provides more specific action compared to traditional chemotherapy, offering effective treatment options with a different mechanism of action. However, like other JAK inhibitors, ruxolitinib phosphate requires careful monitoring due to potential side effects like infections, anemia, and liver enzyme abnormalities.
Specifications:
| Composition | C17H21N6O4P |
| Assay | 99% |
| Appearance | White to off-white powder |
| CAS No. | 1092939-17-7 |
| Packing | Small and bulk |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |
){kind=link}